 NEW YORK, Dec. 09, 2020 GLOBE NEWSWIRE -- Applied Therapeutics, Inc. Nasdaq: APLT, a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced magnetic resonance spectroscopy MRS data on reduction of galactitol levels in the brain of Galactosemia patients treated with AT-007 in the ACTION-Galactodsemia adult study. Overall, plasma reduction in galactitol correlated with brain reduction in galactitol. There were two exceptions, which may have resulted from incomplete peak separation on the MRS scans. At the two doses which demonstrated statistically significant reduction in plasma galactitol, 20 and 40mgkg, 3 out of 4 patients displayed substantial galactitol reduction ranging from 61.94 to 69.80 reduction from baseline. 